The Discern test provides definitive diagnosis of AD as against other forms of dementia. Credit: Steve Buissinne / Pixabay.

Synaps Dx has announced that its Discern test for Alzheimer’s disease (AD) has received proprietary laboratory analyses (PLA) Code 206U and 207U.

This code set is approved by the American Medical Association Current Procedural Terminology (CPT) Editorial Panel.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Discern test is an autopsy-validated, minimally invasive test designed to enable definitive diagnosis of AD as against other forms of dementia in a patient. It uses a small skin sample of the patient to provide clinicians with a diagnosis that has a 95% certainty.

Discern is claimed to be the first AD test of its kind to obtain PLA Code 206U and 207U.

The PLA codes are alpha-numeric CPT codes that are provided with a corresponding descriptor for labs or manufacturers looking to identify their test more specifically.

Synaps Dx CEO and president Frank Amato said: “With a growing number of payers looking at the cost and effectiveness of new drugs and therapies for AD, as well as indicators of early-stage AD and benchmarks for coverage decisions, PLA codes distinguish the market position of Discern and impact reimbursement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Discern is now positioned as a critical, essential component of patient-centric, value-based strategies for providers and payers, with three SDx AD biomarkers that accurately identify and distinguish AD from all other dementias.

“Appropriate medical coding ensures that insurers have all the diagnostic codes necessary for payment.”

The US sees 500,000 new cases of dementia each year. Around two million patients are in the first three years of the disease at any given time.

The use of the Discern test is expected to provide early detection of AD in patients and will facilitate subsequent caregiving.